

# David J Lederer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/123525/publications.pdf>

Version: 2024-02-01

237  
papers

23,081  
citations

17405

63  
h-index

9073

144  
g-index

238  
all docs

238  
docs citations

238  
times ranked

19337  
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing predictors of rheumatoid arthritis-associated interstitial lung disease using quantitative lung densitometry. <i>Rheumatology</i> , 2022, 61, 2792-2804.	0.9	7
2	Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. <i>Respiratory Research</i> , 2022, 23, 3.	1.4	1
3	Associations of Monocyte Count and Other Immune Cell Types with Interstitial Lung Abnormalities. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 795-805.	2.5	11
4	Selective serotonin reuptake inhibitors and lung function in the multi-ethnic study of atherosclerosis lung study. <i>Respiratory Medicine</i> , 2022, 196, 106805.	1.3	0
5	Effect of positive airway pressure therapy of obstructive sleep apnea on circulating Angiotensin-2. <i>Sleep Medicine</i> , 2022, 96, 119-121.	0.8	11
6	Frailty subtypes and recovery in older survivors of acute respiratory failure: a pilot study. <i>Thorax</i> , 2021, 76, 350-359.	2.7	6
7	Associations of $\omega$ -3 Fatty Acids With Interstitial Lung Disease and Lung Imaging Abnormalities Among Adults. <i>American Journal of Epidemiology</i> , 2021, 190, 95-108.	1.6	11
8	Deep Learning of Computed Tomography Virtual Wedge Resection for Prediction of Histologic Usual Interstitial Pneumonitis. <i>Annals of the American Thoracic Society</i> , 2021, 18, 51-59.	1.5	22
9	Risk of primary graft dysfunction following lung transplantation in selected adults with connective tissue disease-associated interstitial lung disease. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 351-358.	0.3	7
10	Obesity-related IL-18 Impairs T-Regulatory Cell Function and Promotes Lung Ischemia-Induced Reperfusion Injury. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1060-1074.	2.5	22
11	Summary for Clinicians: Clinical Practice Guideline on Home Oxygen Therapy for Adults with Chronic Lung Disease. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1444-1449.	1.5	3
12	Hospitalizations in patients with idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2021, 22, 257.	1.4	8
13	The Role of Surgical Lung Biopsy in the Diagnosis of Fibrotic Interstitial Lung Disease: Perspective from the Pulmonary Fibrosis Foundation. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1601-1609.	1.5	8
14	Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. <i>New England Journal of Medicine</i> , 2021, 385, 2230-2240.	13.9	121
15	Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 25-33.	5.2	165
16	Risk factors for disease progression in idiopathic pulmonary fibrosis. <i>Thorax</i> , 2020, 75, 78-80.	2.7	22
17	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 147-157.	5.2	410
18	Associations of Serum Adipokines With Subclinical Interstitial Lung Disease Among Community-Dwelling Adults. <i>Chest</i> , 2020, 157, 580-589.	0.4	17

#	ARTICLE	IF	CITATIONS
19	Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 564-574.	2.5	208
20	Lung Function and Respiratory Symptoms after Tuberculosis in an American Indian Population. The Strong Heart Study. Annals of the American Thoracic Society, 2020, 17, 38-48.	1.5	9
21	Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e121-e141.	2.5	133
22	Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e36-e69.	2.5	508
23	Regional distribution of high-attenuation areas on chest computed tomography in the Multi-Ethnic Study of Atherosclerosis. ERJ Open Research, 2020, 6, 00115-2019.	1.1	9
24	Skeletal muscle adiposity and outcomes in candidates for lung transplantation: a lung transplant body composition cohort study. Thorax, 2020, 75, 801-804.	2.7	12
25	Donor surfactant protein A2 polymorphism and lung transplant survival. European Respiratory Journal, 2020, 55, 1900618.	3.1	19
26	Extended post ex-vivo lung perfusion cold preservation predicts primary graft dysfunction and mortality: Results from a multicentric study. Journal of Heart and Lung Transplantation, 2020, 39, 954-961.	0.3	15
27	Thoracic Visceral Adipose Tissue Area and Pulmonary Hypertension in Lung Transplant Candidates. The Lung Transplant Body Composition Study. Annals of the American Thoracic Society, 2020, 17, 1393-1400.	1.5	9
28	Reference values for high attenuation areas on chest CT in a healthy, never-smoker, multi-ethnic sample: The MESA study. Respirology, 2020, 25, 855-862.	1.3	13
29	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest, 2020, 157, 1506-1512.	0.4	33
30	Antinuclear antibodies and subclinical interstitial lung disease in community-dwelling adults: the MESA study. European Respiratory Journal, 2020, 55, 1902262.	3.1	1
31	Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals. Critical Care Medicine, 2020, 48, 623-633.	0.4	188
32	Association Between Long-term Exposure to Ambient Air Pollution and Change in Quantitatively Assessed Emphysema and Lung Function. JAMA - Journal of the American Medical Association, 2019, 322, 546.	3.8	236
33	Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1402-1413.	2.5	77
34	Circulating adhesion molecules and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis. European Respiratory Journal, 2019, 54, 1900295.	3.1	16
35	Angiotensin Receptor Blockers and Subclinical Interstitial Lung Disease: The MESA Study. Annals of the American Thoracic Society, 2019, 16, 1451-1453.	1.5	8
36	Aryl-Hydrocarbon Receptor Repressor Gene in Primary Graft Dysfunction after Lung Transplantation. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 268-271.	1.4	2

#	ARTICLE	IF	CITATIONS
37	A nonlinear relationship between visceral adipose tissue and frailty in adult lung transplant candidates. <i>American Journal of Transplantation</i> , 2019, 19, 3155-3161.	2.6	25
38	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1146-1153.	2.5	60
39	Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes. <i>Scientific Reports</i> , 2019, 9, 14802.	1.6	12
40	Adipose tissue quantification and primary graft dysfunction after lung transplantation: The Lung Transplant Body Composition study. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 1246-1256.	0.3	29
41	Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design. <i>Advances in Therapy</i> , 2019, 36, 3059-3070.	1.3	4
42	AnnalsATS: New Developments and Advice for Authors. <i>Annals of the American Thoracic Society</i> , 2019, 16, 540-542.	1.5	1
43	Growth differentiation factor-15 as a biomarker of strength and recovery in survivors of acute respiratory failure. <i>Thorax</i> , 2019, 74, 1099-1101.	2.7	7
44	Modeling of Fibrotic Lung Disease Using 3D Organoids Derived from Human Pluripotent Stem Cells. <i>Cell Reports</i> , 2019, 27, 3709-3723.e5.	2.9	175
45	Rice Consumption and Subclinical Lung Disease in US Adults: Observational Evidence From the Multi-Ethnic Study of Atherosclerosis. <i>American Journal of Epidemiology</i> , 2019, 188, 1655-1665.	1.6	6
46	Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). <i>BMJ Open Respiratory Research</i> , 2019, 6, e000422.	1.2	79
47	Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2019, 156, 706-714.	0.4	33
48	Associations of variants in the hexokinase 1 and interleukin 18 receptor regions with oxyhemoglobin saturation during sleep. <i>PLoS Genetics</i> , 2019, 15, e1007739.	1.5	28
49	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 199-208.	2.5	90
50	Generation and persistence of human tissue-resident memory T cells in lung transplantation. <i>Science Immunology</i> , 2019, 4, .	5.6	203
51	Cryobiopsy for Interstitial Lung Disease: The Heat Is On. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1183-1184.	2.5	12
52	Surfactant protein A and D polymorphisms and methylprednisolone pharmacogenetics in donor lungs. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 2109-2117.	0.4	13
53	Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation. <i>Annals of the American Thoracic Society</i> , 2019, 16, 927-930.	1.5	16
54	Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 487-496.	5.2	119

#	ARTICLE	IF	CITATIONS
55	Reply: More on Causal Inference Studies. <i>Annals of the American Thoracic Society</i> , 2019, 16, 646-646.	1.5	0
56	The Annals of the American Thoracic Society Editorial Fellowship Program. <i>Annals of the American Thoracic Society</i> , 2019, 16, 430-430.	1.5	0
57	Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2019, 54, 1901188.	3.1	9
58	Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of <i>Respiratory</i> , <i>Sleep</i> , and <i>Critical Care Journals</i> . <i>Annals of the American Thoracic Society</i> , 2019, 16, 22-28.	1.5	458
59	Bidirectional transfer of Anelloviridae lineages between graft and host during lung transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 1086-1097.	2.6	30
60	Procedure Preference and Intention-to-Treat Outcomes after Listing for Lung Transplantation among U.S. Adults. A Cohort Study. <i>Annals of the American Thoracic Society</i> , 2019, 16, 231-239.	1.5	13
61	Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2019, 155, 712-719.	0.4	24
62	Reply. <i>Arthritis and Rheumatology</i> , 2019, 71, 327-328.	2.9	0
63	Lung Transplantation for Idiopathic Pulmonary Fibrosis. <i>Respiratory Medicine</i> , 2019, , 419-432.	0.1	0
64	Reply: Ethics of Health Research Supported by For-Profit Cannabis Companies: What Have We Learned from Big Tobacco?. <i>Annals of the American Thoracic Society</i> , 2019, 16, 398.	1.5	0
65	Frailty phenotypes and mortality after lung transplantation: A prospective cohort study. <i>American Journal of Transplantation</i> , 2018, 18, 1995-2004.	2.6	95
66	Outcomes and Mortality Prediction Model of Critically Ill Adults With Acute Respiratory Failure and Interstitial Lung Disease. <i>Chest</i> , 2018, 153, 1387-1395.	0.4	29
67	Survival of adults with systemic autoimmune rheumatic diseases and pulmonary arterial hypertension after lung transplantation. <i>Rheumatology</i> , 2018, 57, 831-834.	0.9	4
68	Screening High-Resolution Computed Tomography of the Chest to Detect Interstitial Lung Disease in Systemic Sclerosis: A Global Survey of Rheumatologists. <i>Arthritis and Rheumatology</i> , 2018, 70, 971-972.	2.9	38
69	A novel patient-centered "intention-to-treat" metric of U.S. lung transplant center performance. <i>American Journal of Transplantation</i> , 2018, 18, 226-231.	2.6	13
70	Associations between emphysema-like lung on CT and incident airflow limitation: a general population-based cohort study. <i>Thorax</i> , 2018, 73, 486-488.	2.7	19
71	Quantitative Evidence for Revising the Definition of Primary Graft Dysfunction after Lung Transplant. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 235-243.	2.5	45
72	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1036-1044.	2.5	174

#	ARTICLE	IF	CITATIONS
73	A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2018, 153, 94-104.	0.4	66
74	2018 Clinical Practice Guideline Summary For Practicing Clinicians: Diagnosis of Idiopathic Pulmonary Fibrosis. <i>Annals of the American Thoracic Society</i> , 2018, 16, 285-290.	1.5	20
75	Optimizing Home Oxygen Therapy. An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1369-1381.	1.5	49
76	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. <i>BMJ Open Respiratory Research</i> , 2018, 5, e000289.	1.2	48
77	Focus on Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2018, 154, 978-979.	0.4	10
78	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, e44-e68.	2.5	2,678
79	Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey. <i>BMC Pulmonary Medicine</i> , 2018, 18, 9.	0.8	112
80	Idiopathic Pulmonary Fibrosis. <i>New England Journal of Medicine</i> , 2018, 378, 1811-1823.	13.9	1,177
81	The Phillip Morris Foundation for a Smoke-Free World. A Cause for Concern. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1269-1272.	1.5	2
82	Recurrent diffuse lung disease due to surfactant protein C deficiency. <i>Respiratory Medicine Case Reports</i> , 2018, 25, 91-95.	0.2	11
83	Idiopathic Pulmonary Fibrosis. <i>New England Journal of Medicine</i> , 2018, 379, 795-798.	13.9	114
84	Collagen biomarkers and subclinical interstitial lung disease: The Multi-Ethnic Study of Atherosclerosis. <i>Respiratory Medicine</i> , 2018, 140, 108-114.	1.3	11
85	Serum 25-Hydroxyvitamin D Concentrations Are Associated with Computed Tomography Markers of Subclinical Interstitial Lung Disease among Community-Dwelling Adults in the Multi-Ethnic Study of Atherosclerosis (MESA). <i>Journal of Nutrition</i> , 2018, 148, 1126-1134.	1.3	5
86	Cell-free hemoglobin promotes primary graft dysfunction through oxidative lung endothelial injury. <i>JCI Insight</i> , 2018, 3, .	2.3	35
87	Quantitative analysis of adipose tissue on chest CT to predict primary graft dysfunction in lung transplant recipients: a novel optimal biomarker approach. , 2018, , .		0
88	Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation. <i>Annals of the American Thoracic Society</i> , 2017, 14, 172-181.	1.5	91
89	Peripheral Blood Gene Expression Changes Associated With Primary Graft Dysfunction After Lung Transplantation. <i>American Journal of Transplantation</i> , 2017, 17, 1770-1777.	2.6	17
90	The Frailty Phenotype and Palliative Care Needs of Older Survivors of Critical Illness. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 1168-1175.	1.3	31

#	ARTICLE	IF	CITATIONS
91	Diagnosing idiopathic pulmonary fibrosis without a lung biopsy: honeycombing not required. <i>Thorax</i> , 2017, 72, 391-392.	2.7	4
92	Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study. <i>Thorax</i> , 2017, 72, 472-474.	2.7	29
93	Plasma Soluble Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis. <i>Annals of the American Thoracic Society</i> , 2017, 14, 628-635.	1.5	28
94	Refining Low Physical Activity Measurement Improves Frailty Assessment in Advanced Lung Disease and Survivors of Critical Illness. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1270-1279.	1.5	35
95	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1249-1254.	2.5	166
96	High-Attenuation Areas on Chest Computed Tomography and Clinical Respiratory Outcomes in Community-Dwelling Adults. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1434-1442.	2.5	58
97	Obstructive Sleep Apnea and Subclinical Interstitial Lung Disease in the Multi-Ethnic Study of Atherosclerosis (MESA). <i>Annals of the American Thoracic Society</i> , 2017, 14, 1786-1795.	1.5	60
98	Antacid use and subclinical interstitial lung disease: the MESA study. <i>European Respiratory Journal</i> , 2017, 49, 1602566.	3.1	5
99	Serum Matrix Metalloproteinase-7, Respiratory Symptoms, and Mortality in Community-Dwelling Adults. MESA (Multi-Ethnic Study of Atherosclerosis). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1311-1317.	2.5	35
100	Race, Ethnicity, Health Insurance, and Mortality in Older Survivors of Critical Illness. <i>Critical Care Medicine</i> , 2017, 45, e583-e591.	0.4	15
101	Patient-centered Outcomes in Idiopathic Pulmonary Fibrosis Clinical Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 674-675.	2.5	1
102	Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 22-32.	5.2	200
103	Frailty and maximal exercise capacity in adult lung transplant candidates. <i>Respiratory Medicine</i> , 2017, 131, 70-76.	1.3	25
104	Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1514-1522.	1.5	39
105	Occupational Exposures and Subclinical Interstitial Lung Disease. The MESA (Multi-Ethnic Study of) Tj ETQq1 1 0.784314 rgBT /Overl... <i>Annals of the American Thoracic Society</i> , 2017, 196, 1031-1039.	2.5	46
106	Air pollution and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA) airâ€lung study. <i>European Respiratory Journal</i> , 2017, 50, 1700559.	3.1	86
107	Genome-wide association study of subclinical interstitial lung disease in MESA. <i>Respiratory Research</i> , 2017, 18, 97.	1.4	31
108	The Perioperative Lung Transplant Virome: Torque Teno Viruses Are Elevated in Donor Lungs and Show Divergent Dynamics in Primary Graft Dysfunction. <i>American Journal of Transplantation</i> , 2017, 17, 1313-1324.	2.6	96

#	ARTICLE	IF	CITATIONS
109	Adipose Gene Expression Profile Changes With Lung Allograft Reperfusion. American Journal of Transplantation, 2017, 17, 239-245.	2.6	10
110	Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respiratory Medicine, 2017, 5, 33-41.	5.2	240
111	AnnalsATS 2022: Rigor, Value, Impact. Annals of the American Thoracic Society, 2017, 14, 1753-1754.	1.5	2
112	Chest Fat Quantification via CT Based on Standardized Anatomy Space in Adult Lung Transplant Candidates. PLoS ONE, 2017, 12, e0168932.	1.1	21
113	Smoking and Subclinical ILD in RA versus the Multi-Ethnic Study of Atherosclerosis. PLoS ONE, 2016, 11, e0153024.	1.1	19
114	Living with Interstitial Lung Disease: How Do We Best Meet the Educational Needs of Our Patients?. Annals of the American Thoracic Society, 2016, 13, 1001-1002.	1.5	0
115	Impact of the Arg 16 allele of the B2AR gene on the effect of withdrawal of LABA in patients with moderate to severe asthma. Journal of Asthma, 2016, 53, 783-789.	0.9	5
116	Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP. American Journal of Transplantation, 2016, 16, 833-840.	2.6	23
117	Primary graft dysfunction: Long-term physical function outcomes among lung transplant recipients. Heart and Lung: Journal of Acute and Critical Care, 2016, 45, 544-549.	0.8	8
118	Rheumatoid arthritis-associated autoantibodies and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis. Thorax, 2016, 71, 1082-1090.	2.7	59
119	Per cent emphysema is associated with respiratory and lung cancer mortality in the general population: a cohort study. Thorax, 2016, 71, 624-632.	2.7	61
120	Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax, 2016, 71, 429-435.	2.7	151
121	Cryobiopsy in the Diagnosis of Interstitial Lung Disease. A Step Forward or Back?. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 707-709.	2.5	25
122	The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia. Journal of Heart and Lung Transplantation, 2016, 35, 500-507.	0.3	30
123	Frailty in Pulmonary and Critical Care Medicine. Annals of the American Thoracic Society, 2016, 13, 1394-1404.	1.5	67
124	A Novel Picture Guide to Improve Spiritual Care and Reduce Anxiety in Mechanically Ventilated Adults in the Intensive Care Unit. Annals of the American Thoracic Society, 2016, 13, 1333-1342.	1.5	38
125	High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study. European Respiratory Journal, 2016, 48, 1442-1452.	3.1	110
126	Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. European Respiratory Journal, 2016, 48, 843-851.	3.1	134

#	ARTICLE	IF	CITATIONS
127	Donor lung assessment using selective pulmonary vein gases. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, 826-831.	0.6	16
128	Reply: Disparities in Access to Lung Transplantationâ€™More Than Meets the Eye. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 643-644.	2.5	0
129	Idiopathic Pulmonary Fibrosis on the Internet. Letâ€™s Calm the Sea of (Mis)information. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 134-136.	2.5	1
130	Polysomnographic Measurement of Sleep Duration and Bodily Pain Perception in the Sleep Heart Health Study. <i>Sleep</i> , 2016, 39, 1583-1589.	0.6	16
131	Fat segmentation on chest CT images via fuzzy models. , 2016, , .		2
132	Fat quantification and analysis of lung transplant patients on unenhanced chest CT images based on standardized anatomic space. <i>Proceedings of SPIE</i> , 2016, , .	0.8	0
133	Seeking and sharing: why the pulmonary fibrosis community engages the web 2.0 environment. <i>BMC Pulmonary Medicine</i> , 2016, 16, 4.	0.8	18
134	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 265-275.	2.5	1,006
135	Short Stature and Access to Lung Transplantation in the United States. A Cohort Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 681-688.	2.5	32
136	Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. <i>European Respiratory Journal</i> , 2016, 47, 243-253.	3.1	349
137	Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. <i>BMJ Open Respiratory Research</i> , 2016, 3, e000105.	1.2	96
138	Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , 2016, 13, 25-30.	1.5	53
139	Association of Forced Vital Capacity with the Developmental Gene NCOR2. <i>PLoS ONE</i> , 2016, 11, e0147388.	1.1	17
140	Objective Estimates Improve Risk Stratification for Primary Graft Dysfunction after Lung Transplantation. <i>American Journal of Transplantation</i> , 2015, 15, 2188-2196.	2.6	51
141	A comparison of visual and quantitative methods to identify interstitial lung abnormalities. <i>BMC Pulmonary Medicine</i> , 2015, 15, 134.	0.8	39
142	Interleukin-6 and Tumor Necrosis Factor-Î± Are Associated with Quality of Lifeâ€™Related Symptoms in Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , 2015, 12, 370-375.	1.5	31
143	Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2015, 148, 196-201.	0.4	35
144	Survival of Adults With Systemic Sclerosis Following Lung Transplantation: A Nationwide Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1314-1322.	2.9	72

#	ARTICLE	IF	CITATIONS
145	Editors' Introduction to Annals ATSClinical Research Design Articles. Annals of the American Thoracic Society, 2015, 12, 1436-1437.	1.5	0
146	Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1200-1207.	2.5	101
147	Frailty Phenotypes, Disability, and Outcomes in Adult Candidates for Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1325-1334.	2.5	181
148	Neutrophil Extracellular Traps Are Pathogenic in Primary Graft Dysfunction after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 455-463.	2.5	187
149	A consensus document for the selection of lung transplant candidates: 2014 "An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 1-15.	0.3	1,121
150	Intravenous Immunoglobulin for Hypogammaglobulinemia after Lung Transplantation: A Randomized Crossover Trial. PLoS ONE, 2014, 9, e103908.	1.1	14
151	Body Composition and Mortality after Adult Lung Transplantation in the United States. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1012-1021.	2.5	108
152	Interstitial Lung Disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Annals of the American Thoracic Society, 2014, 11, S169-S177.	1.5	37
153	The feasibility of measuring frailty to predict disability and mortality in older medical intensive care unit survivors. Journal of Critical Care, 2014, 29, 401-408.	1.0	73
154	A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370, 2083-2092.	13.9	2,959
155	Preoperative Plasma Club (Clara) Cell Secretory Protein Levels Are Associated With Primary Graft Dysfunction After Lung Transplantation. American Journal of Transplantation, 2014, 14, 446-452.	2.6	18
156	Embracing Complex Diseases. The Case for an Idiopathic Pulmonary Fibrosis Biorepository. Annals of the American Thoracic Society, 2014, 11, 1248-1249.	1.5	2
157	Genome-wide association analysis identifies six new loci associated with forced vital capacity. Nature Genetics, 2014, 46, 669-677.	9.4	131
158	Plasma Complement Levels Are Associated with Primary Graft Dysfunction and Mortality after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1564-1567.	2.5	30
159	Genetic Variation in the Prostaglandin E <sub>2</sub> Pathway Is Associated with Primary Graft Dysfunction. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 567-575.	2.5	32
160	Association Between Emphysema-like Lung on Cardiac Computed Tomography and Mortality in Persons Without Airflow Obstruction. Annals of Internal Medicine, 2014, 161, 863.	2.0	72
161	Lung Transplantation for Idiopathic Pulmonary Fibrosis. , 2014, , 363-377.		2
162	Lung Transplantation and Atrial Septostomy in Pulmonary Arterial Hypertension. Clinics in Chest Medicine, 2013, 34, 857-865.	0.8	10

#	ARTICLE	IF	CITATIONS
163	Donor Surfactant Protein D (SP-D) Polymorphisms Are Associated With Lung Transplant Outcome. American Journal of Transplantation, 2013, 13, 2130-2136.	2.6	24
164	Gene Set Enrichment Analysis Identifies Key Innate Immune Pathways in Primary Graft Dysfunction After Lung Transplantation. American Journal of Transplantation, 2013, 13, 1898-1904.	2.6	66
165	Disparities in lung transplantation. Journal of Heart and Lung Transplantation, 2013, 32, 673-674.	0.3	4
166	High Burden of Palliative Needs among Older Intensive Care Unit Survivors Transferred to Post-acute Care Facilities. A Single-Center Study. Annals of the American Thoracic Society, 2013, 10, 458-465.	1.5	37
167	Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis. European Respiratory Journal, 2013, 41, 1324-1330.	3.1	32
168	Preoperative Serum Albumin Levels Predict 1-Year Postoperative Survival of Patients Undergoing Heart Transplantation. Circulation: Heart Failure, 2013, 6, 785-791.	1.6	35
169	Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward. European Respiratory Journal, 2013, 42, 1446-1448.	3.1	5
170	Clinical Risk Factors for Primary Graft Dysfunction after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 527-534.	2.5	529
171	Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan. Annals of Internal Medicine, 2013, 158, 641.	2.0	437
172	Donor Age and Early Graft Failure After Lung Transplantation: A Cohort Study. American Journal of Transplantation, 2013, 13, 2685-2695.	2.6	46
173	Pilot Study Exploring Lung Allograft Surfactant Protein A (SP-A) Expression in Association With Lung Transplant Outcome. American Journal of Transplantation, 2013, 13, 2722-2729.	2.6	26
174	Latent Class Analysis Identifies Distinct Phenotypes of Primary Graft Dysfunction After Lung Transplantation. Chest, 2013, 144, 616-622.	0.4	48
175	A Prognostic Model for 6-Month Mortality in Elderly Survivors of Critical Illness. Chest, 2013, 143, 910-919.	0.4	56
176	An Acute Change in Lung Allocation Score and Survival After Lung Transplantation. Annals of Internal Medicine, 2013, 158, 650.	2.0	39
177	Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis. European Respiratory Journal, 2013, 41, 1324-1330.	3.1	20
178	Is Obstructive Sleep Apnea a Cause of Idiopathic Pulmonary Fibrosis?. Archives of Pathology and Laboratory Medicine, 2012, 136, 470-470.	1.2	19
179	The Renin-Angiotensin System and Right Ventricular Structure and Function: The MESA-Right Ventricle Study. Pulmonary Circulation, 2012, 2, 379-386.	0.8	26
180	Socioeconomic Barriers to Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 937-939.	2.5	7

#	ARTICLE	IF	CITATIONS
181	Secondary Prevention of Idiopathic Pulmonary Fibrosis: Catching the Horse Still in the Barn. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 697-699.	2.5	7
182	Pulmonary Capillary Wedge Pressure Augments Right Ventricular Pulsatile Loading. Circulation, 2012, 125, 289-297.	1.6	369
183	Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis. European Respiratory Journal, 2012, 39, 359-365.	3.1	40
184	Plasma Endothelin-1 and Vascular Endothelial Growth Factor Levels and Their Relationship to Hemodynamics in Idiopathic Pulmonary Fibrosis. Respiration, 2012, 84, 299-305.	1.2	11
185	Plasma monocyte chemotactic protein-1 levels at 24 hours are a biomarker of primary graft dysfunction after lung transplantation. Translational Research, 2012, 160, 435-442.	2.2	26
186	Sildenafil for Chronic Obstructive Pulmonary Disease: A Randomized Crossover Trial. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2012, 9, 268-275.	0.7	88
187	A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation. Journal of Heart and Lung Transplantation, 2012, 31, 942-949.	0.3	53
188	Variation in <i>PTX3</i> Is Associated with Primary Graft Dysfunction after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 546-552.	2.5	68
189	Elevated Plasma Angiopoietin-2 Levels and Primary Graft Dysfunction after Lung Transplantation. PLoS ONE, 2012, 7, e51932.	1.1	28
190	Selecting lung transplant candidates: where do current guidelines fall short?. Expert Review of Respiratory Medicine, 2012, 6, 51-61.	1.0	67
191	Postoperative Estradiol Levels Associate With Development of Primary Graft Dysfunction in Lung Transplantation Patients. Gender Medicine, 2012, 9, 154-165.	1.4	5
192	Translational Research in Lung Transplantation: How Do We Get From Mouse to Human?. American Journal of Transplantation, 2012, 12, 281-282.	2.6	0
193	Hypoalbuminemia and Early Mortality After Lung Transplantation: A Cohort Study. American Journal of Transplantation, 2012, 12, 1256-1267.	2.6	44
194	A comparison of single breath and re-breathe diffusing capacity in emphysema patients and controls. Respiratory Physiology and Neurobiology, 2012, 183, 15-19.	0.7	4
195	Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT. Contemporary Clinical Trials, 2011, 32, 280-287.	0.8	8
196	Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension. Circulation, 2011, 123, 2985-2993.	1.6	127
197	Elevated Plasma Clara Cell Secretory Protein Concentration Is Associated with High-Grade Primary Graft Dysfunction. American Journal of Transplantation, 2011, 11, 561-567.	2.6	37
198	Elevated Plasma Long Pentraxin-3 Levels and Primary Graft Dysfunction After Lung Transplantation for Idiopathic Pulmonary Fibrosis. American Journal of Transplantation, 2011, 11, 2517-2522.	2.6	51

#	ARTICLE	IF	CITATIONS
199	Lung Volume Reduction Surgery Using the NETT Selection Criteria. <i>Annals of Thoracic Surgery</i> , 2011, 91, 1556-1561.	0.7	24
200	Obesity and Primary Graft Dysfunction after Lung Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 1055-1061.	2.5	135
201	Two, One, or None for Chronic Obstructive Pulmonary Disease: Who Decides and How?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 1226-1227.	2.5	2
202	Micromechanics of Alveolar Edema. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 44, 34-39.	1.4	108
203	Delayed Access and Survival in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 842-847.	2.5	229
204	Elevated Pulmonary Artery Pressure Is a Risk Factor for Primary Graft Dysfunction Following Lung Transplantation for Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2011, 139, 782-787.	0.4	85
205	Effect of Single vs Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2011, 140, 489-496.	0.4	18
206	Vascular Inflammation in Obesity and Sleep Apnea. <i>Circulation</i> , 2010, 121, 1014-1021.	1.6	214
207	Construct validity of the definition of primary graft dysfunction after lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 1231-1239.	0.3	128
208	Endothelial repair capacity and apoptosis are inversely related in obstructive sleep apnea. <i>Vascular Health and Risk Management</i> , 2009, 5, 909.	1.0	61
209	Soluble P-Selectin and the Risk of Primary Graft Dysfunction After Lung Transplantation. <i>Chest</i> , 2009, 136, 237-244.	0.4	34
210	Plasma Levels of Receptor for Advanced Glycation End Products, Blood Transfusion, and Risk of Primary Graft Dysfunction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 1010-1015.	2.5	145
211	Cigarette Smoking Is Associated with Subclinical Parenchymal Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 407-414.	2.5	227
212	Obesity and Underweight Are Associated with an Increased Risk of Death after Lung Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 887-895.	2.5	158
213	Circulating KL-6, a biomarker of lung injury, in obstructive sleep apnoea. <i>European Respiratory Journal</i> , 2009, 33, 793-796.	3.1	43
214	Quantification of single-breath underestimation of lung volume in emphysema. <i>Respiratory Physiology and Neurobiology</i> , 2009, 165, 215-220.	0.7	18
215	Tacrolimus and Azathioprine Versus Cyclosporine and Mycophenolate Mofetil After Lung Transplantation: A Retrospective Cohort Study. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 697-703.	0.3	14
216	Serum Albumin Concentration and Waiting List Mortality in Idiopathic Interstitial Pneumonia. <i>Chest</i> , 2009, 135, 929-935.	0.4	48

#	ARTICLE	IF	CITATIONS
217	Platelet activation in the postoperative period after lung transplantation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 135, 679-684.	0.4	18
218	Assessment of Kidney Function in Lung Transplant Candidates. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 635-641.	0.3	10
219	The Modification of Diet in Renal Disease (MDRD) and the Prediction of Kidney Outcomes After Lung Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 1191-1197.	0.3	16
220	Plasma serotonin levels are normal in pulmonary arterial hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008, 21, 112-114.	1.1	25
221	Use of an Interferon- $\gamma$ Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients. <i>Chest</i> , 2008, 133, 869-874.	0.4	41
222	Platelets Enhance Endothelial Adhesiveness in High Tidal Volume Ventilation. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2008, 39, 569-575.	1.4	24
223	Outcomes after Lung Retransplantation in the Modern Era. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 114-120.	2.5	116
224	Racial Differences in Waiting List Outcomes in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 450-454.	2.5	45
225	Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2007, 132, 998-1006.	0.4	223
226	Risk Factors for Venous Thromboembolism After Lung Transplantation. <i>Chest</i> , 2007, 132, 547-553.	0.4	54
227	Update in Surgical Therapy for Chronic Obstructive Pulmonary Disease. <i>Clinics in Chest Medicine</i> , 2007, 28, 639-653.	0.8	15
228	Lung-volume reduction surgery for pulmonary emphysema: Improvement in body mass index, airflow obstruction, dyspnea, and exercise capacity index after 1 year. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 133, 1434-1438.	0.4	34
229	Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2006, 19, 370-374.	1.1	59
230	Osteoporosis in Diffuse Parenchymal Lung Disease. <i>Chest</i> , 2006, 129, 140-146.	0.4	36
231	Racial and Ethnic Disparities in Survival in Lung Transplant Candidates with Idiopathic Pulmonary Fibrosis. <i>American Journal of Transplantation</i> , 2006, 6, 398-403.	2.6	62
232	Racial and Ethnic Disparities in Idiopathic Pulmonary Fibrosis: A UNOS/OPTN Database Analysis. <i>American Journal of Transplantation</i> , 2006, 6, 2436-2442.	2.6	60
233	Immunoglobulin G Levels before and after Lung Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 917-921.	2.5	57
234	Six-Minute-Walk Distance Predicts Waiting List Survival in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 659-664.	2.5	339

#	ARTICLE	IF	CITATIONS
235	Outcomes of Extended Donor Lung Recipients after Lung Transplantation. <i>Transplantation</i> , 2005, 79, 310-316.	0.5	52
236	Successful Bilateral Lung Transplantation for Pulmonary Fibrosis Associated With the Hermansky-Pudlak Syndrome. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1697-1699.	0.3	52
237	LUNG VOLUME REDUCTION SURGERY IMPROVES THE BODE INDEX. <i>Chest</i> , 2005, 128, 178S.	0.4	1